uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
1. uniQure's AMT-130 shows significant efficacy in Huntington's disease treatment. 2. Study met primary endpoint with 75% slower disease progression (p=0.003). 3. Company raised $175 million to support AMT-130's commercial launch. 4. Shares surged 189.82% to $39.59, a new 52-week high. 5. AMT-130 showed a good safety profile with manageable adverse events.